Introduction
Materials and Methods
Study Population
Data Collection
Data Analysis
Results
Characteristic | n (%) or median (IQR) |
---|---|
Age (years) | 48 (41–57) |
Female | 17 (68%) |
WHO region | |
Region of the Americas | 11 (44%) |
African region | 12 (48%) |
European region | 2 (8%) |
Self-identified area of expertisea | |
Clinician/healthcare worker | 16 |
Researcher | 15 |
Ethicist | 4 |
Policy developer | 1 |
Recruitment category | |
HIV treatment/prevention in women | 12 (48%) |
HIV treatment/prevention pediatrics | 3 (12%) |
HIV policy | 5 (20%) |
PrEP investigator | 5 (20%) |
Experience in HIV/MCH (years) | 12 (10–23) |
Developing Evidence-Based Therapies for Pregnant Women
Experts reported that strict exclusion of pregnant women from upstream research displaces risks downstream to clinical care. As they explained, restricting research because of concerns for the safety of the unborn child limits availability of safety data, which ultimately constrains clinicians’ ability to provide evidence-based therapies for pregnant women.“I really do appreciate the sentiment of wanting to be careful, but I think it ends up being that because of this lag, we end up treating women inadequately and inappropriately for periods of time while we wait for data to appear.” Participant 716; healthcare provider, region of the Americas
Experts expressed concern that the decision to move to implementation of new interventions in pregnant women is often based on studies with non-pregnant women, leading to untested assumptions about safety during pregnancy or continuation of possibly harmful pre-pregnancy medications.“I think too much caution means that people are just doing stuff on their own when it could lead to more potential harm than doing it in at least a study setting when you [are] gathering more data. I think we need more information, and research is the way to get it.” Participant 586; healthcare worker/researcher, region of the Americas
Several experts noted that medical practice and research remain haunted by past experiences with under-studied drugs, such as thalidomide, which caused serious fetal harm. The resulting fear of fetal harm was thought to be the reason for imposing a high barrier to investigating therapies for pregnant women, inadvertently creating evidence gaps for preventing or treating illness during pregnancy.“I’m on listservs where all these smart people start using whatever great-looking antiretroviral combination is working so well when the woman is not pregnant, and they just continue it during pregnancy. That’s crazy.… They should change to something that they know is safer or safe until there’s enough data to show safety and efficacy in the pregnant woman.” Participant 408; healthcare worker, region of the Americas
When asked about the reasons that might justify greater inclusion of pregnant women in research, most participants thought that investigating treatments for severe conditions affecting women during pregnancy, including HIV, should be given priority. When probed, those participants believed it unethical to exclude pregnant women from research studies when the condition was severe and the interventions could provide direct benefit to the pregnant woman.“We are so afraid [of fetal risk] that we don’t make a way to investigate this important time…. Because we have not investigated that time of a woman’s life…we’ll have interventions for babies, for adolescents, for non-pregnant women, but the pregnant women will always remain uninvestigated.” Participant 978; researcher, African region
While it was a minority view among experts, a few maintained that classifying pregnant women as a vulnerable population was warranted and extra precautions should be taken, even if these precautions slow development of new interventions for use during pregnancy.“[I]f it’s a drug that might be needed to treat a condition in a woman that is serious, not studying it in pregnancy to me seems unethical… [A]nd on the other hand, just saying that you could study any drug in a pregnant woman, that doesn’t seem right either. So again, it depends on, to me, what the condition is, whether one studies it or not, and I would like to see more studies in pregnant women than less…instead [of being] reliant on observational gossip.” Participant 328; researcher, region of the Americas
“Pregnant women are [a] vulnerable group and just like [a] vulnerable group, they must be protected…. [W]hile we need more information for research, pregnancy is very sensitive and they must be protected, because certain damages done around that period may cause irreversible harm, so it’s a balancing act, whatever drives the research must be a balancing act.” Participant 527; healthcare worker/researcher/ethicist, African region
Triangulation of Evidence for Evaluating Treatments in Pregnancy
In the absence of RCT data, all experts described triangulating and extrapolating data from animal studies, clinical case reports, and registry or post-market surveillance data to make decisions.“[T]here will never be randomized controlled trial data on most of these things because anything that’s going to show up on an RCT would’ve had such a strong signal in preclinical trials that it would never have gotten there. … For me, the real question is, ‘How can you generate enough registry data to give yourself some confidence that you really believe it?’” Participant 408; healthcare worker, region of the Americas
However, many experts were quick to caution against several common errors in this approach. First was the need for careful consideration when extrapolating from currently available data to a different setting or population—important biological, genetic, and environmental differences could limit the meaningfulness of data from a particular population. Second, some experts noted that early reports of adverse outcomes, anecdotes, or case studies can be weighted heavily, and can stop interventions from moving forward to implementation research in pregnancy.“[T]he more different sources of data we have, the easier it is to make decisions and to not feel like you are making decisions in the absence of information and that you can make informed decisions….” Participant 131; researcher, African region
Other experts described how stories about single adverse events travel quickly and can breed mistrust among frontline clinicians and in the community, reducing uptake of potentially beneficial interventions, and reducing community members’ willingness to participate in research.“I think many people are really influenced by anecdotal evidence and it usually just messes things up. I think it’s very important to have the real hard evidence in making these decisions, because RCTs would give us good evidence that would help us to make decisions based on some research being done properly.” Participant 978; researcher, African region
“[T]he use of Efavirenz is another good example, where we had some animal data and some case reports suggesting issues with neural tube defects with use in the first few weeks of the pregnancy. [A]lthough that wasn’t definitive data, based on that, the FDA changed their recommendations. … In use later, we had no indication that there was an issue from the observational data…. So one could’ve said, ‘Well, you can’t use this drug in the first four weeks, but you can use it afterwards,’ but rather the FDA and the European group went way out and said, ‘You should never take this drug during pregnancy,’ which was an over-interpretation of the data.” Participant 328; researcher, region of the Americas
A Nuanced Approach Needed When Balancing Maternal–Fetal Risk and Benefit
Position on maternal–fetal priority | Rationale offered | Example quotes |
---|---|---|
Prioritize woman over pregnancy | She can have another pregnancy/have another child but we can’t get another “her” | “I think the woman’s health should be a priority because she stands to get another pregnancy, so if she loses the one pregnancy she’s carrying or if she gets problems developing [the one] that she’s carrying, she’s still able to get another pregnancy. But, when we have a baby who can’t take care of themselves, the risks in the mother leads her to death, then we are enveloped in the hopeless situation of trying to raise this baby.” Participant 691; healthcare worker, African region “We know that if the mother loses the pregnancy, there is an opportunity to have another baby, but if we lose both the mother and the baby, that is a loss, so usually that is why we say that the mother is the priority.” Participant 992; healthcare worker, African region “As an obstetrician, I cannot delink the two…..as I take care of the health of the mother, the health of the baby is also important, but situations arise where [a] decision can be made in the interest of the health of the mother, but those are specific situations…..when you now know that is the only option you have, then you may make a decision in the interest of the mother that the mother will live for another day to have another baby. But those are really specific situations and cannot be generalized.” Participant 527; healthcare worker/researcher/ethicist, African region |
Prioritize woman as patient | She’s the “living” patient | “A woman’s health takes priority. I mean you’re obviously going to consider both, but…….I mean she’s your patient at the outset. She’s the living object of your intervention until the baby’s born.” Participant 586; healthcare worker/researcher, region of the Americas “I think the mother’s health should be the priority, because we’re trying to protect the unborn baby not knowing whether it will be born alive or not…so I think the health of the mother should be the first priority in this case.” Participant 995; researcher, African region “[M]y experience from [country in sub-Saharan Africa] is that the fetus is not viewed as prominently as it is in [Western country], or it doesn’t seem to have as much importance…..because in countries like [country in sub-Sarahan Africa] so many infants die, that it’s much more accepted there than it is [in Western country], and I’m not saying that’s a good thing. But there’s also a greater tendency among obstetricians to give medications that we might not give in [Western country], knowing that there’s a risk to the fetus, because they don’t have other options. And so there is less attention paid to teratogenicity in countries like [country in sub-Saharan Africa].” Participant 980; healthcare worker, region of the Americas |
Prioritize avoiding infant harm | Infant priority with serious risk of harm | “If we know that the risk to the infant is going to be severe, I think that absolutely matters. And if it’s [an] 80% chance that something’s going to happen to the infant, then there’s really no point rolling out that option, treatment or prevention.” Participant 309; healthcare worker/researcher/policy developer, European region |
Mother first, because infant survival depends on her | Infant survival depends on the mother being alive | “And you know actually, the survival of children to a large extent is dependent on the survival of the mother, especially in our part of the world. And when you lose the mother, chances of losing the baby are also very high.” Participant 202; healthcare worker/researcher/ethicist, African region “….the ideal is to have a healthy mother in the future who can participate as much as possible in caring and raising the unborn child.” Participant 741; healthcare worker/researcher, region of the Americas “I would always go for the mother, protecting the life of the mother over the child, because of what we know and what evidence has shown about the risks to a child if the mother is unwell or the mother dies, then the child is at a higher risk, and especially in developing countries, so I would consider the health of the mother first and then the one of the infant.” Participant 373; healthcare worker, African region |
Mother first, because family and community depend on her | She’s the mother of other children - think about her in terms of larger impact on community/family | “I think the health of the woman is absolutely paramount…. as much as there is concern regarding fetal exposure and fetal health, if we’re causing ill health to the woman, however small or big, I think that is something that really needs to be put into the balance, simply because she may be the mother of other children who need her, and she is a big contributor to the community and not only to her own family, and so it is absolutely paramount that the women’s health and women’s position be kept important in any decision, whether it’s research or in a clinical setting.” Participant 309; healthcare worker/researcher/policy developer, European region “If there is a definite benefit to the mother, then that is a treatment one needs to look at very favorably, because in the end, if the mother survives or if you are able to get out of danger, then not only is she able to look after any other children she has, but she can also get others. So, I mean, the benefits to the mother is the final consideration, and a very important one.” Participant 202; healthcare worker/researcher/ethicist, African region |
Holistic | Healthy mom = healthy baby (in terms of treating an illness that might adversely affect the pregnancy) | “I feel like ultimately, even if I were to only think about the infant, it’s in the infant’s best interest to have a healthy mom. So I would say prioritize the maternal health because in fact a side effect of that is infant health.” Participant 716; healthcare worker, region of the Americas “I guess I’m always gonna land on what you would consider the side of the mother. But to me, the mother and the baby are sort of inseparable units, but if you’re treating the mother, it’s gonna benefit the baby in general.” Participant 796; healthcare worker, region of the Americas “[P]ersonally, I think [the health of] both is important and the mother’s health is critically important in order for ensuring that her infant reaches term and is delivered safely, so I don’t think her health should be excluded from the equation. But similarly, there should be a priority based on delivering a healthy infant and ensuring that there are no harms to that child because any harms to that child are likely to be life long and likely to be the responsibility of that women and her family and therefore, it’s important to bear that in mind as well.” Participant 131; researcher, African region |
Other experts holding more woman-centered views along the spectrum strongly defended prioritizing the woman’s health on consequentialist grounds. These reasons included: (1) she can go on to have other children if she loses this pregnancy; (2) she has responsibilities to other children, her family, and her community; and (3) the infant’s survival and future well-being depend on the woman’s health.“I’m a maternalist, so I don’t see the life of the mother and the life of the fetus as equal. I think we need to put appropriate safeguards in place and do as little harm as possible to the fetus, but always keeping in mind that the mom’s life comes first. [G]enerally the way that I think about it is, if a mom really needs a drug for her health, then we need to treat her like she is not pregnant.” Participant 980; healthcare worker, region of the Americas
When asked how the interests of the woman and her unborn baby ought to be balanced in the context of HIV prevention, and more generally in the provision of any intervention during pregnancy, experts considered the severity of the illness in the woman against the likelihood of fetal harm as the main consideration. When the illness was severe and the mother’s life was in jeopardy, these experts prioritized intervention regardless of the impact to fetal health.“[A]s a clinician, both are your patients and the infant’s health is tied to the mother’s health…..The mother’s health is critically important for ensuring that her infant reaches term and is delivered safely, so I don’t think her health should be excluded from the equation. But similarly, there should be a priority based on delivering a healthy infant and ensuring that there are no harms to that child because any harms to that child are likely to be life long and likely to be the responsibility of that woman and her family.” Participant 131; researcher, African region
When evaluating outcomes, the majority of experts placed more weight on known harms to the mother or fetus when compared to potential fetal harms. In certain situations, known fetal harms trumped potential benefits to the woman.“The maternal health piece, in almost all cases, would be the primary consideration; you would want to be sure that you are treating a woman for a serious condition adequately, and unless you knew that the agent being used had serious consequences for the fetus, the maternal benefit would outweigh it, and potentially, if you had a life-threatening illness in the mother, even if you knew that there might be a problem in the fetus, one might consider moving forward, if you were saving that woman’s life.” Participant 328; researcher, region of the Americas
Some experts thought it always ethically required to minimize the use of treatments with potential or unknown risks to the fetus, except when there is no alternative for the mother, and this position was often accompanied by reflection on past controversies. One participant appealed to the future child’s right to as open and healthy future as possible.“[T]he sicker the woman and the more provenly beneficial the treatments are for the woman’s sickness, the more likely you are to accept the potential for known or unknown risk to the fetus.” Participant 408; healthcare worker, region of the Americas
“Well, you know there’s the old Thalidomide story, right? That the potential for harm and the lives of those people born with the harmful effects, I think they too have the right to the potential of a healthy future life, so the issue of protecting the unborn fetus so that when they’re born, they’re born as healthy as is possible, is important.” Participant 660; researcher, African region
Considering Economic Factors, Logistical Considerations, and Cultural Attitudes About Women’s Autonomy in Local Contexts
Within resource-constrained settings, medication costs play a large role in treatment decisions during pregnancy. Cost and limited financial resources can impact the availability and acceptability of treatment options when women or in-country policy makers are asked to balance medication costs with treatment effectiveness and the availability of alternative treatment options.“I think the social and economic context of the clinical care and research is always part of the equation, too. [W]omen in some places are desperate for good medical care, and some places they’re not. And I think when we talk about how we’re going to take care of women when they’re pregnant… we can’t divorce ourselves from that economic and social context, which affects every decision that they make, basically.” Participant 782; researcher/ethicist, region of the Americas
In addition to cost, logistical factors, such as dosing, availability of alternative options, and pick-up location were important practical factors experts considered when making treatment decisions. Medications requiring too much time, follow-up, or intensive care were recognized as not likely to be taken up by women and therefore less likely to be prescribed.“PrEP has great potential [for] preventing infection. But we have so many people who need treatment and I think sometimes I understand the dilemma of the policy maker because with the resources they have, who do they give [PrEP to], do they give to the sick or do they use the resources to prevent new people from getting [sick]…? We don’t have the unlimited resources.” Participant 202; healthcare worker/researcher/ethicist, African region
All experts described the challenges of navigating social and cultural attitudes towards the role of women in decision-making, including attitudes of deference from women themselves. In situations of uncertainty, when information or data are imperfect, experts still believed it is important to share what is known with women. This was especially true in situations where the decision is complex and both the mother’s health and the health of the fetus are in jeopardy. Clinicians, in particular, felt it was important to make such a decision with a woman as a shared decision, to support women in weighing the risks and benefits as known, together. Overall, the more uncertainty present in the risk/benefit equation, the more experts wanted the woman to be informed and make her own choice, but with support. Clinical experts reported that women differ in their desire for information and involvement in decisions and found it challenging when women defer to their expertise, but they do not have sufficient evidence on which to base a recommendation.“[W]ithin the environments where we work you’ve got overloaded services already. We battle to get women into four antenatal visits. We battle to get HIV-positive women into three monthly visits for testing, and negative [women] for testing…Anything that’s just too demanding is going to be highly challenging, unless it’s just a very small number of women that require that level of intensity to treat them, like diabetics…And I know it’s a consideration for the woman because if she’s having to take time off work, pay for fare, spend a day sitting in the clinic, you know she’s not going to be keen to do that either.” Participant 539; researcher, African region
Clinical experts also found it difficult to navigate conversations with pregnant women who prioritized the safety of the fetus at the expense of their own health, with some noting that they would feel obligated to advocate for the woman’s health in such a case.“Some women want to be very involved with every decision-making, and there are some women who simply want a clinician to tell them what the clinician thinks is best. And that’s tricky when it’s a grey area and the clinician can’t say definitely what’s best.” Participant 221; healthcare worker, region of the Americas
Similarly, clinical experts described the cultural challenges surrounding women’s deference to male partners and expectations in some cultural contexts that male partners must be involved in decisions potentially affecting a woman’s pregnancy. Several experts took a pragmatic approach in considering male partners’ views in contexts where they knew women were likely to defer to husbands.“[M]ost of them in my experience, whether it’s in Europe or in Africa, most women will have a bias towards the baby’s health…but I think it’s up to us to help make sure that we balance that a little bit. If something is really dangerous for the health of the woman…we should really advise them towards their own health.” Participant 136; healthcare worker/researcher/ethicist, European region
Finally, several clinical experts made an important observation about the role of women in making decisions around new interventions for use in pregnancy, noting that particularly in developing countries, women are seldom brought into the decision-making processes about when and what new drugs and interventions are made available to pregnant women in the first place.“The male partner becomes an important player and stakeholder, and quite often even after you have discussed issues with the women, they defer, they don’t make a decision, they want to go and consult first, so that becomes important because whatever he decides is probably what is going to carry the day.” Participant 202; healthcare worker/researcher/ethicist, African region
“I’ve heard this in these conversations where people are talking about rolling out PrEP… particularly in the developing world… where there’s this very patriarchal way of thinking: there are bodies of people who are going to make decisions about what’s best for women, and that kind of rubs me the wrong way. I still think that there has to be this theme through what we do about giving them the information and then helping them in making the choice that works best for them. Participant 221; healthcare worker, region of the Americas